Investing.com - Cellectis reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Cellectis announced earnings per share of $-0.88 on revenue of $14.62M. Analysts polled by Investing.com anticipated EPS of $-0.7301 on revenue of $11.1M.
Cellectis shares are down 49.33% from the beginning of the year, still down 60.50% from its 52 week high of $34.71 set on January 20. They are under-performing the Nasdaq which is up 15.57% from the start of the year.
Cellectis shares lost 1.53% in after-hours trade following the report.
Cellectis follows other major Healthcare sector earnings this month
Cellectis's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
UnitedHealth had beat expectations on July 15 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar